Merck (MRK) Other Accumulated Expenses (2009 - 2026)

Merck has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $14.5 billion for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 13.91% year-over-year to $14.5 billion; the TTM figure through Mar 2026 stood at $14.5 billion (up 13.91% YoY), while the FY2025 annual figure was $14.5 billion, down 7.81% from the prior year.
• Other Accumulated Expenses improved to $14.5 billion in Q1 2026, from $14.5 billion in the prior quarter.
• Over the last five years, Other Accumulated Expenses for MRK reached as high as $16.5 billion in Q3 2024 and fell as low as $12.8 billion in Q1 2025.
• The 5-year median for Other Accumulated Expenses is $14.5 billion (2025), against an average of $14.5 billion.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses grew 17.97% — and 2025, when it fell 9.43%.
• A 5-year view of Other Accumulated Expenses shows it stood at $14.2 billion in 2022, then climbed by 11.35% to $15.8 billion in 2023, then retreated by 0.46% to $15.7 billion in 2024, then declined by 7.81% to $14.5 billion in 2025, then gained by 0.56% to $14.5 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $14.5 billion, $14.5 billion, and $16.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.